

# Francisco J Esteva

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8347926/publications.pdf>

Version: 2024-02-01

38  
papers

2,414  
citations

279487

23  
h-index

344852

36  
g-index

38  
all docs

38  
docs citations

38  
times ranked

4720  
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 2078-2099.	0.8	303
2	Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1179-1183.	3.0	280
3	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. <i>Cancer</i> , 2012, 118, 2603-2614.	2.0	265
4	Clinical utility of gene-expression signatures in early stage breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 595-610.	12.5	197
5	Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. <i>Oncotarget</i> , 2014, 5, 9864-9876.	0.8	188
6	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 2100-2108.	0.8	165
7	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2736-2740.	0.8	141
8	CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. <i>Lancet Oncology</i> , The, 2017, 18, 917-928.	5.1	93
9	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2804-2807.	0.8	93
10	Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype. <i>Scientific Reports</i> , 2017, 7, 41960.	1.6	73
11	Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy. <i>Clinical Breast Cancer</i> , 2016, 16, 113-122.e1.	1.1	49
12	Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 329-341.	1.1	49
13	Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process. <i>Oncotarget</i> , 2018, 9, 12868-12878.	0.8	46
14	Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	42
15	High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts. <i>International Journal of Cancer</i> , 2018, 143, 3027-3034.	2.3	41
16	Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 382-386.	1.1	36
17	Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2â€“positive metastatic breast cancer. <i>Cancer</i> , 2014, 120, 1932-1938.	2.0	35
18	Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers. <i>Clinical Cancer Research</i> , 2015, 21, 1098-1105.	3.2	35

#	ARTICLE	IF	CITATIONS
19	HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. <i>Molecular Oncology</i> , 2015, 9, 586-600.	2.1	31
20	DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer. <i>Oncotarget</i> , 2017, 8, 77207-77218.	0.8	30
21	Optimizing outcomes in HER2-positive breast cancer: the molecular rationale. <i>Oncology</i> , 2005, 19, 4.	0.4	30
22	Gene Signatureâ€“Guided Dasatinib Therapy in Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5265-5271.	3.2	28
23	Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 1003-1009.	2.9	28
24	Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2â€“) advanced breast cancer (ABC): Results from MONALEESA-3.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1000-1000.	0.8	21
25	Optimizing outcomes in HER2-positive breast cancer: the molecular rationale. <i>Oncology</i> , 2005, 19, 5-16.	0.4	20
26	What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e117-e125.	1.8	13
27	Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. <i>Clinical Breast Cancer</i> , 2019, 19, 268-277.e1.	1.1	13
28	Breast cancer risk in relation to plasma metabolites among Hispanic and African American women. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 687-696.	1.1	13
29	Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7388-7395.	3.2	12
30	Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 921-930.	1.9	11
31	Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2â€“) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET); MONALEESA-3.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS624-TPS624.	0.8	11
32	The current status of docetaxel for metastatic breast cancer. <i>Oncology</i> , 2002, 16, 17-26.	0.4	6
33	Genome-Based Risk Prediction for Early Stage Breast Cancer. <i>Oncologist</i> , 2014, 19, 1019-1027.	1.9	5
34	Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors. <i>Clinical Cancer Research</i> , 2021, 27, 5343-5352.	3.2	5
35	Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1124-TPS1124.	0.8	3
36	Genomic Signatures in Breast Cancer: Limitations of Available Predictive Data and the Importance of Prognosis. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 25-31.	0.3	3

#	ARTICLE	IF	CITATIONS
37	Detection of metastases in breast cancer: Is whole body PET/MR better than PET/CT?. Journal of Clinical Oncology, 2014, 32, 15-15.	0.8	0
38	Abstract 5469: Trastuzumab resistant HER2+ breast cancer cells retain sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition. , 2014, , .		0